Alex Root

TL;DR: The literature of studies using SRM‐MS in systems biology and clinical proteomics is surveyed to advance the understanding of biological networks and the phenotypic significance of specific network states and to advance biomarkers into clinical use.

TL;DR: Next-generation biomarkers need to discriminate disease from benign controls with high sensitivity and specificity for an intended use, which is a two-tiered strategy of identifying and screening high-risk patients, and much more investment is needed to overcome challenges.

TL;DR: The PiHelper framework integrates human drug-target and antibody-target associations from publicly available resources to help meet the needs of researchers in systems pharmacology, perturbation biology and proteomics.

TL;DR: The question of efficacy of drug combinations and development of resistance mechanisms to targeted therapy by a systems pharmacology approach is addressed and the combination of systematic drug perturbation combined with detailed observation of short-term molecular response using mass spectrometry is a potentially powerful tool to discover response markers and anti-resistance targets.

TL;DR: Through data integration of three proteomics data sets, BV02 modulates numerous protein-protein interactions involving 14-3-3 proteins in PCa models and has a high binding affinity for other drugs used to treat PCa such as docetaxel.